More recently, in the KEYNOTE-811 study, the combination of pembrolizumab with trastuzumab and chemotherapy for HER2-positive GC/GEJ cancers demonstrated a significant improvement in response rate [123]. This evidence concerns the gene ERBB2 and gastric cancer.